Appears on
Articles5
Novartis to pay $1.1B upfront for UK biotech Myricx to expand the pharma's ADC pipeline
Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a novel payload.
Kaileraās oral GLP-1 asset sees 11% weight loss, hits goals in Chinese phase 3 obesity and diabetes trials
Phase 3 trials of Kailera Therapeuticsā oral GLP-1 prospect have hit their primary endpoints, positioning the biotechās partner Hengrui Pharma to seek approval in obesity and diabetes in China.
Boehringer bags PVTās viral vector platform for cancer vaccine R&D
Boehringer Ingelheim has landed an exclusive license to Prime Vector Technologiesā viral vector platform for developing next-generation cancer vaccines.
AstraZeneca pens $2.1B Sino deal for challenger to Merckās COPD drug Ohtuvayre
AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & Co.ās chronic obstructive pulmonary disease drug Ohtuvayre.
Satellosā āintriguingā Duchenne data raise hopes ahead of key readout
Satellos Bioscience has shared evidence that its Duchenne muscular dystrophy drug candidate is active in adults, leading analysts to predict the molecule ācould re-imagine the ... therapeutic landscapeā if the biotech replicates the data in children.